<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800046</url>
  </required_header>
  <id_info>
    <org_study_id>1436</org_study_id>
    <nct_id>NCT00800046</nct_id>
  </id_info>
  <brief_title>A Study of Percutaneous Treatment of Mitral Regurgitation Using the AccuCinch® System</brief_title>
  <official_title>A Study of Percutaneous Treatment of Mitral Regurgitation Using the AccuCinch® System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ancora Heart, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ancora Heart, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective single-arm study of the AccuCinch® Ventriculoplasty System in the treatment of
      mitral valve regurgitation through subvalvular mitral repair.

      Purpose: To demonstrate the safety, feasibility and potential efficacy of using the
      AccuCinch® Ventriculoplasty System to reduce mitral valve regurgitation through subvalvular
      mitral repair.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety through 30 days and reduction in MR acutely and at 30 days.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and reduction in MR at 1 year.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Functional Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>AccuCinch® Ventriculoplasty System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AccuCinch® Ventriculoplasty System</intervention_name>
    <description>Mitral valve repair due to functional disease</description>
    <arm_group_label>AccuCinch® Ventriculoplasty System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mitral regurgitation grade of ≥ 2+ (Germany) and ≥ 3+(Canada)

          -  Ejection Fraction ≥ 30%

          -  Patient is eligible for surgical mitral valve repair or replacement

          -  Confirmation by the Medical Monitor that patient has met all eligibility criteria and
             no exclusion criterion

          -  The patient has been informed of the nature of the study, agrees to its provisions,
             and has provided written informed consent

        Exclusion Criteria:

          -  Myocardial infarction within 90 days of the intended treatment with the device

          -  Prior surgical, transcatheter, or percutaneous mitral valve intervention

          -  Any intervention for coronary artery disease (CAD) within the last 3 months prior to
             treatment, or known requirement for revascularization within the next 12 months

          -  Hemodynamic instability or the need for emergent surgery

          -  NYHA Class IV symptoms of heart failure

          -  History of bacterial endocarditis

          -  History of bleeding diathesis or coagulopathy

          -  History of stroke within the prior 6 months

          -  Any angiographic or clinical evidence that the investigator feels would place the
             patient at increased risk with the placement of the device or concurrent medical
             condition with a life expectancy of less than 12 months

          -  Co-morbid conditions that place the subject at an unacceptable surgical risk or any
             contraindication to mitral valve surgery

          -  Subjects require concomitant cardiac surgical repair such as other mitral repair
             techniques, coronary artery bypass graft (CABG), aortic valve replacement, tricuspid
             repair or replacement, left ventricular remodeling surgery and congenital repair

          -  Female patients who are pregnant, of child bearing potential or lactating

          -  Patients who are unable or unwilling to comply with the follow-up schedule
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Schofer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Care Center Prof. Mathey, Prof. Schofer, GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Zapien, MS, CCRA</last_name>
    <phone>408-727-1105</phone>
    <phone_ext>204</phone_ext>
    <email>mzapien@ancoraheart.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Vertesich</last_name>
      <email>markus.vertesich@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Irene Lang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg-Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Waldmann-Kittler</last_name>
      <email>tefanie.Waldmann-Kittler@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Rothe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Bettin</last_name>
      <email>d.bettin@immanuel.de</email>
    </contact>
    <investigator>
      <last_name>Christian Bütter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rüdiger Gebauer</last_name>
    </contact>
    <investigator>
      <last_name>Helge Möllmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabea Wagstaff</last_name>
      <email>Rabea.Wagstaff@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Ralf Westenfeld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ardiovascular Center Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine de Bruijn</last_name>
      <email>s.debruijn@cvcfrankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Horst Sievert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Care Center Hamburg University Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kerstin Flint</last_name>
      <email>flint@herz-hh.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Schofer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Krefeld Niederrhein</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Bufe</last_name>
      <email>alexander.bufe@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Alexander Bufe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roza Meyer-Saraei</last_name>
      <email>Roza.Meyer-Saraei@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Desch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silke Plattfaut</last_name>
      <email>s.plattfaut@bk-trier.de</email>
    </contact>
    <investigator>
      <last_name>Karl Eugen Hauptmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>November 16, 2017</last_update_submitted>
  <last_update_submitted_qc>November 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral valve</keyword>
  <keyword>Mitral regurgitation</keyword>
  <keyword>Functional mitral regurgitation</keyword>
  <keyword>MR</keyword>
  <keyword>FMR</keyword>
  <keyword>Heart valve</keyword>
  <keyword>Mitral valve insufficiency</keyword>
  <keyword>Valve repair</keyword>
  <keyword>Valve disorder</keyword>
  <keyword>Cardiac surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

